Voronoi, Inc. · KRX:310210
Voronoi — Non-Deal Roadshow (June 2023)
28 slides from Voronoi's roadshow presentation, Jun 28, 2023
Slide 1: IR Book
Creating Novel Therapeutics By People With Excellent Expertise In Drug Design 2023.06 IR Book
Slide 2: Disclaimer
Investor Relations 2023 <> VORONOI Disclaimer FEE 7 EAS S HYSS MAIS Presentationol|M2| Git MSS SACS Helo] FAIS|AHOlot “SIA}")Ol] fot ASIEISLICH 2] SIF OSHS BAIS BI AHPAPIS O|0 [St = Xo Bete! “SSS 71H SO! SAS 7AA| BES SSSALCh Of B17 Of Olao| Aa} Bhi! Atetoe SIA HAQORS ‘Oly, Mey, ‘AS, ICH, (©! Sz} AS
Slide 3: Content
Creating Novel Therapeutics By People With Excellent Expertise In Drug Design CONTENT
Slide 4: Drug Design Technology
Crea Novel Therapeutics By Pe With Excellent Expertise In Drug Design™ ® VORONOI & . Vr Drug Design Technology VORONOI Overview SA 7|S=0ll 7[bSt 71S OMe Bat Business Model SFE AI7i] SHAN 71S @ "MEHelectivity)” OSA] SHY 71S @ “S-SerSY Sap" Pret MENS & -S EPS aS Pipeline AuPwnag
Slide 5: VORONOI Overview
Investor Relations 2023 VORONOI Overview AB 2015.02. (2022.06. At&t) CHEER Zc, SIE AAI OMAHA) SS Tse] 32 AES AloppHst FQ eof soln] GI LA] AIS BAR| ZA| caer 11404 Medchem Lab <> OrIC VORONO! = Atel ee7e (Bb | | | | | i ~19 *20.10 21.01 21.08 21.11 *22.09 Biology Lab Preclinical,Genter VORONOI 5
Slide 6: Technology transfer and partnership deals
[42] TELIASO 71 01 Investor Relations 2023 o xz =| PS As SAA 7| SHO 7[bst 71S 014/435 Sut = Mel S SA OFAN 7/Bel Stet D CH7/ZICHE T}o|ma}OI TS D AlH MS BS MSS Bee HENS Sst TEL} Clelst BEA Tey New Target PDGFR / [S94 a1sley . HER2+/ ister © METis RIPK1/AP}HAAISt Pan-RAF / Hilo}, SAW S arsyot. 44 8.220
Slide 7: Business Model
Investor Relations 2023 Business Model Discovery Eto] HAS USolo] MAag~-27 |aiet Ct7ilall 71S OM HEL O| Aop7yet BMA &¥P} License-Out “Movie SSBHS Best Ve “21st BHO] BE ME Qein}o| SS 7H" Oe 712i EE 7H” Discovery Capability AZ SHS US Hole] + Over 5 50 000 vear 230,000 20M 5M 4,000 50 164,000 10,000 12,
Slide 8: Selectivity-focused drug design
Investor Relations 2023 oral atl 71 © “MEH A1(Selectivity)” 202014 FDA Sole! /BxI7} SZ ots ee Ut mam MEY SSO "SET BAe |” MEHAO|| UH Sts7} Sas H|-AMISEm|OF RET EL % 1274] Ala 71B 21EAl Cabometyx ZBPSIS (06): 28 7\E CHS ELM &/2m) CHI “AEH AT JH — 850 SS 71 AZT AIS (%): 69 + WHY 21S Kinase ABIES Leb +
Slide 9: Brain penetration (BBB) design
Investor Relations 2023 crear a4) 71 @ “Me|- SABLA Say” 71E 42 SHE ‘}R10| Sto] CHS OBZ O| oFS9] S|-SEHY Sats SS ols ~ Blood ae steal ‘een ee B&. ¢ brain Barrier | i I i | Se dle 27 Mols= ate, OHSS 4] tPF Blood-Brain Barrier, BBB) Fiber | das 20] L140] Eve . 10) " Bos 33” A ge Sos £8 2 gs 304. Be! Fy
Slide 10: Brain penetration of pipeline candidates
Investor Relations 2023 SAS! MENA & | SPH ahs 24st MEH BI 25S tp |-S47hRHH (Blood-Brain Barrier, BBB) =7}SS 7 SH Sa) SS BEX Top-tier +E MHS VRN11 RIK) DYRK1A/CLK 2: Eurofins VORONO! S:320| SS &/-SPHy Sas >100% 71% 60~90% 50-90% | EGFR C797S_ EGFR Exon20 HER2 BRAF RIPK1(CNS) ins. + EGFR C797 Double M
Slide 11: Pipeline
Inve: stor Relations 2023 Pipeline Bet, ELAS] Meat L|Z Soil Met Cterst SEKS| 7/BOMS olletet Target Partner Alot H|z rs “y lore: 1,300 S! LAMaitet ORIC ren tH eel 2,1008F tet LYASE ARIAL Wet, 2k 4eslet inno.N HIE AIAfoH| Cet L7H a CBAZIO| AY HAYEIE, . jor: 5008F Tecan OBrickellbic BAB Sor seh 404 2 3
Slide 12: VRN11 EGFR program
Crea Novel Therapeutics By Pe With Excellent Expertise In Drug Design™ ® VORONODI & ® & * ~N 8 3 Neat S ee 3 € » Vr VRN11, EGFR H|AA22TH/St X) =A] VRN11. Resistance mutations in EGFR VRN11. MEH offetarget Toxicity7t HAs] SS OFetst OF VRN11. EGFR E42 |2 Al] |-SPry tS VRN11. Technical Feasibility in-v
Slide 13: VRN11. Resistance mutations in EGFR
Investor Relations 2023 VRN11. Resistance mutations in EGFR VRN112 EE HIAAM[SEH|2t EGFR TKls 7H2ES GD dug ©) unmet Needs EGFR TKls Potency 4|i SLs LE 3h $= Uncommon Gilotrif DTC LTC DTC LTC at} BSLHoOe EGFR SAHO| A|=Al0l] Zaloh= Ctetet Unmet Needs stZ 7ts Double Mutation Drug + #3 )) cis-iT¢ \_TbleM
Slide 14: VRN11. Resistance mutations in EGFR
Investor Relations 2023 VRN11. Resistance mutations in EGFR lressa, Tarceva > Tagrisso 2fOl| CHE SIS Lys EGFR TKls Potency D EGFR Mutation Potency 3 D L DT LT Dc Lc ' Iressa, Tarceva D, Las & okig Sold 12} lea Sel Tagrisso2| 14} AEA] SO! OF SIE Lis Tagrisso D DC L LC VRN11 => I = & @& D, Loll cSt Po
Slide 15: VRN11. EGFR Uncommon mutation
Investor Relations 2023 VRN11. EGFR Uncommon mutation EGFR TKls Potency EGFR Mutation Potency G719X 1861Q s7egyy — FX0N20 Uncommon Mutation 1%} 1274] ins. 5s = THB SHES! LiCHS stat) Tagrisso Gilotrif Gilotrif VRNO7 t VRN11 (ORIC-114) 1 CriC i 4 @& EGFR Uncommon Mutationol| LHSt Potency 8! LHSPO = PL
Slide 16: VRN11. Resistance mutations in EGFR
Investor Relations 2023 VRN11. Resistance mutations in EGFR VRN112 EGFR SAHO| XA 01] ZAHSH= CoFSt Unmet Needs siZd 7kS EGFR TKls Potency H|i EGFR Mutation EGFR Uncommon Mutation Drug D L DT LT Dc Lc G L s Iressa, Tarceva Gilotrif Tagrisso VRN11 L: EGFR L858R, D: EGFR Del19, T:EGFR T790M, C: EGFR C79
Slide 17: VRN11. Off-target toxicity
Investor Relations 2023 VRN11. ATEHAS off-target Toxicity7} 1415] KES OBIS OFS QIAS BOl AMAL OBO] Setslx| RE ABO| Mew Shes OTHER ‘1: Eurofins Discover Kinomescan, 1 uM concentration top 10% cutoff, >x30-fold offtargets excluded TAT BOS S-core(10) 0.24 BIA} BS: S-core(10) 0.13 VORONO!_ 17
Slide 18: Brain and CSF distribution of EGFR-TKIs
100% Mouse Rat Table 2. Summary of healthy rat brain and CSF distribution constants, Kp and Kpuu, plus brain and plasma binding, fuplasma and fubrain, for 16 EGFR-TKIs. 75% Drug Brain Kp CSF Kp fuplasma % fubrain % Brain Kpuu CSF Kpuu Osimertinib 6.09 0.0047 1.66 (0.22) 0.057 (0.012) 21.0% 29.0% Tag
Slide 19: VRN11 potency by EGFR mutation
0.01 0.005 Gilotrif WT 0 Del19 L858R DC LC Uncommon G719A Mutations G719C G719S
Slide 20: In-vivo efficacy
Vehicle Vehicle Osimertinib (12.5 mpk) VRN11 (5 mpk) Erlotinib (50 mpk) VRN11 (10 mpk) VRN11 (20 mpk) VRN11 (3 mpk) VRN11 (10 mpk) VRN11 (30 mpk)
Slide 21: VRN11. Clinical Trial Study Plan phase 1b expansion
Investor Relations 2023 VRN11. Clinical Trial Study Plan phase 1b expansion SHEAIOl MEYOm O12) EGFR SAOlOl| CHS! Ef BtZI0] 74S VRN11, Phase 1b expansion plan v. 3 1028 OSS ASS EGFR Mutation Brain metastasi ation Drug Dc -_ C7978 te |Molztat Bet Monotherapy @& Blueprint Medicines > Zai Lab BUS Cli],
Slide 22: VRN11. NSCLC market
Investor Relations 2023 VRN11. NSCLC AJ24 H|AM|ZEH|2F EO fl] SAHO|S + AHO] Aaa aa HAMS] SAO Sit + AR(%) EGFR C7975 30.24 3.96 1.28) 18 40) 45,3~46.3 JIEt EGFR EGFR RET FEL O1S Cts] SO} 37H HO] EGFR SAO] SYBO| 1.6~2tH Ole SS (SH 48%, Wet 45%, SEH 43% - OF 26%, HEI 15%) H|AMSEH|22| SAHOO OFS APA] LL O
Slide 23: VRN10 HER2+ program
Crea Novel Therapeutics By Pe With Excellent Expertise In Drug Design™ ® VORONOI & Don HER2+ SHtot x] =A VRN10. HER2+ Introduction VRN10. HER2+ 2c so She oe VRN10. AEH VRN10. HER2+ s/-setahe at outer x len] BWNo
Slide 24: VRN10. HER2+ introduction
Investor Relations 2023 VRN10. HER2+ introduction Treatment Landscape for HER2 Positive Metastatic Breast Cancer after DBO9 clinical trial Systemic Therapy for HER2 Positive Metastatic Breast Cancer Taxane + Trastuzumab + Pertuzumab T-Dxd T-DM1 Tucatinib + Trastuzumab + Capecitabine + Other options
Slide 25: VRN10. HER2+ differentiation
Investor Relations 2023 VRN10. HER2+ eye se sHeace $5, UG SAHO|, | Fat YESS 71 Kt AL Rb ir a7 4| lS FOE 23S SS SHES 7\% TKls & VRN10 H|at Wild EGFR Sparing (EGFR1 CHE] EGFR2 MIEHAS) <5 <10 >100x >100x ADC 82 ALA| Covalent Covalent Non-covalent Non-covalent (Covalent Inhibitor) (but poor tolerability
Slide 26: VRN10. Selectivity
Investor Relations 2023 VRN10. MEHAY Sli WS ofS0| SSOlA| Ret RO] MEAS Stet Neratinib Tucatinib BA: Euroins VORONO!_ 26
Slide 27: VRN10. HER2+ brain metastasis efficacy
Investor Relations 2023 VRN10. HER2+ 4-324 =a} 224A} CH] Se} SIPS St ZO| Ss Patients (%) ator Sixt Se] Bo] WAHL | Ho] SBOIAl SF 87} 1=107 1x108 Total flux [Photon/s] 5 : Internal Research Data 5 _ ae 10 15 20 Days after treatment et AEA Ho SSe &| M0] Sol = mouse Vehicle Tucatinib (75 mpk/BID) VRN10
Slide 28: Thank You
Creating Novel Therapeutics By People With Excellent Expertise In Drug Design Thank You